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Nonimmunologic complications and gene polymorphisms of
immunoregulatory cytokines in long-term renal transplants.
Background. While the influence of cytokine gene polymor-
phisms on immunologic complications after organ transplanta-
tion is widely evaluated, little is known about predictive value
of cytokine genotype for the development of nonimmunologic
post-transplant complications: hypertension, dyslipoproteine-
mia, diabetes mellitus, hyperuricemia.
Methods. The −1082IL-10, −308TNF-a, transforming
growth factor-b1 (TGF-b1) (codon 10, 25), −174IL-6,
+874IFN-c gene single nucleotide polymorphisms (SNP) were
studied in 278 long-term renal transplants by polymerase chain
reaction-sequence specific primer (PCR-SSP) with respect to
nonimmunologic post-transplant complications.
Results. Significant association of the TGF-b (codon 25) GG
genotype with hyperuricemia (P = 0.0013) and dyslipopro-
teinemia (P = 0.0171) was found. The TGF-b1 (codon 25) CG
genotype was detected more frequently in patients with normal
uric acid levels. The +874IFN-c AA genotype was associated
with type 2/steroid-induced diabetes (P = 0.0127). Frequency
of the −1082IL-10 AG genotype was significantly higher in
hyperuricemic patients versus controls (P = 0.0022). No as-
sociations of polymorphisms in the tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6), TGF-b codon 10 genes with hy-
peruricemia, dyslipoproteinemia, or diabetes were detected.
We failed to observe significant differences in cytokine genotype
distribution between hypertensive and normotensive patients.
Conclusion. We established an association of particular cy-
tokine genotypes with nonimmunologic post-transplant com-
plications. This supports an idea that assessment of cytokine
SNPs may allow more accurate prediction of nonimmunologic
complications and appropriate adjustment of pre-emptive treat-
ments in long-term transplant patients.
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Cytokine gene polymorphisms have been shown to
be involved in the susceptibility, clinical performance,
and outcome in a variety of diseases [1]. While the
influence of cytokine gene polymorphisms on various
immunologic complications after solid organ transplan-
tation is widely evaluated [2], little is known about the
predictive value of cytokine genotype for the develop-
ment of nonimmunologic post-transplant complications.
As survival after transplantation improves, several med-
ical complications develop more frequently during long-
term postoperative periods, including a high incidence
of hypertension, post-transplant diabetes mellitus, and
hyperlipidemia [3]. The emergence of these pathologic
conditions is generally thought to be mediated by di-
rect effects of immunosuppressive medications [4]. Two
representative examples are the diabetogenic effect of
steroids [5] and the cyclosporine-induced inhibition of
insulin production by b cells [6]. However, recent find-
ings indicate that certain proinflammatory cytokines are
capable of interfering with insulin-sensitive glucose up-
take and induce insulin resistance [7], as well as affect-
ing adipose tissue metabolism [8] and modulating blood
pressure [9]. Intriguingly, a member of “adipocytokine”
family, TNF-a is over-expressed in the adipose tissue
of obese humans [10], and contributes to insulin resis-
tance by up-regulating free fatty acid secretion, inhibit-
ing insulin signaling in adipocytes, and down-regulating
glucose transporters [11]. Interferon-c (IFN-c), a proin-
flammatory cytokine primarily known for its roles in im-
munologic responses, also has been shown to elicit insulin
resistance, which is accompanied by the regulation of
various adipocyte transcription factors, in particular, in-
hibiting the synthesis and stimulating the degradation of
peroxisome proliferator-activated receptor c (PPARc)
[12]. Notably, the IFNc-induced regulation of PPARc
might have clinical importance because of the associa-
tion between PPARc, insulin resistance, type 2 diabetes,
and early onset hypertension in man [13]. TGF-b , a
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multifunctional cytokine that controls cell growth, differ-
entiation, and extracellular matrix production, has been
reported to inhibit insulin signaling in human preadipose
cells [14], and has been implicated in the pathogenesis
of atherosclerotic vascular disease [15] and hypertension
[16].
Collectively, given the indicated pathophysiologic
role of particular proinflammatory cytokines in glucose
turnover, lipid metabolism, and increased blood pressure,
and provided that cytokine SNPs in certain nonimmuno-
logic post-transplant complications (i.e., diabetes mel-
litus, dyslipoproteinemia, hypertension, hyperuricemia)
have been little studied, we analyzed the −1082IL-10,
−308TNF-a, TGF-b1 (codon 10, 25), −174IL-6, and




DNA samples were obtained from 278 Caucasoid re-
nal transplant patients (163 men and 115 women, pa-
tient age 51.3 ± 12 years, transplant age 5.6 ± 4 years)
consecutively admitted from March 2002 to August 2002
to the transplant outpatient unit of the Department of
Nephrology and Internal Intensive Care, University Hos-
pital Charite´, Campus Virchow, Berlin. The study was
approved by the local hospital ethical committee, and in-
formed consent was obtained from all subjects.
The patients were under triple (cyclosporine or
tacrolimus + prednisone and ATG or anti-IL-2R-
antibody as induction therapy) or quadriple (triple +
MMF) immunosuppressive regimen. Parameters as-
sessed in the study were clinical symptoms of atheroscle-
rotic vascular disease and resting blood pressure (RBP)
levels. Routine laboratory tests included cholesterol,
triglycerides, fasting blood glucose (FBG), and uric acid
levels. Patients with type 2/steroid-induced diabetes mel-
litus (T2/SIDM), hypertension (RBP ≥140/95 mm Hg or
sustained use of antihypertensive drugs), hyperuricemia
[uric acid ≥6.5 mg/dL (women), ≥6.9 mg/dL (men) or
treatment with uricosuric agents], and dyslipoproteine-
mia were distinguished. Those patients, who had normal
post-transplant FBG, RBP, uric acid, and lipid profiles
served as controls. There were no significant differences
regarding the age, gender, immunosuppressive regimen,
and the transplant age between the study and the control
patients.
Genotyping
DNA was obtained from 200 lL of citrated peripheral
blood using a commercially available DNA extraction kit
(QIAamp Blood Kit, Qiagen, Hilden, Germany) accord-
ing to manufacturer’s instructions.
Analysis of TNF-a, TGF-b, LI-6, IL-10, and
IFN-c gene polymorphism
The PCR-SSP was performed using commercially
available cytokine genotyping primer pack (One
Lambda, Meerbusch-Osterath, Germany) according to
manufacturer’s instructions. Briefly, 50 to 100 ng of iso-
lated DNA in the volume of 1 lL were added to the
master mix, which consisted of 7 lL D-Mix, 0.05 lL Tag
polymerase (5 U/lL), and 2 lL of appropriate primer.
Cycling was performed at 96◦C for 130 seconds, 63◦ for
60 seconds, followed by 9 cycles at 96◦C for 10 seconds,
63◦ for 60 seconds, 20 cycles at 96◦ for 10 seconds, 59◦ for
50 seconds, and 72◦ for 30 seconds. The amplified prod-
ucts were monitored by electrophoresis on a 2% agarose
gel containing ethidium bromide (0.5 lg/mL), visualized
with UV light on a transilluminator, and photographed.
Statistical analysis
Frequencies of genotypes were estimated from the ob-
served data. Hardy-Weinberg equilibrium was assessed
for the genotype distribution. Contingency 2 × 2 tables
were constructed, and the Yate’s corrected chi-square test
was run to determine statistical significance of differences
in genotype frequency for the cytokine SNPs in control
and study patients. P values of <0.05 were considered
statistically significant. Post-hoc comparisons were made
using multivariate multi-way between-groups analysis of
variance (MANOVA) in order to ensure that factors such
as post-transplant time period, type of native disease, or
type of donor was not a confounding variable, and that
the genotype related association is an independent risk
factor.
RESULTS
We have evaluated the homozygous and heterozygous
frequencies for the −1082IL-10, −308TNF-a, TGF-b1
(codon 10, 25), −174IL-6, and +874IFN-c SNPs in a
group of long-term renal transplant patients with re-
spect to nonimmunologic post-transplant complications
(Table 1).
There was a significant increase in the +874IFN-c AA
genotype in the patients with T2/SIDM compared with
the control nondiabetic patients. A significant increase in
the TGF-b1 (codon 25) GG genotype was observed both
in patients affected by hyperuricemia and dyslipopro-
teinemia. Conversely, the TGF-b1 (codon 25) CG geno-
type was detected more frequently in the patients with
normal uric acid levels. The frequency of the −1082IL-
10 AG genotype was significantly higher in the hyper-
uricemic patients compared with the control patients.
We failed to observe significant differences in the
IL-6, TNF-a, TGF-b1 (codon 10) genotype distribu-
tion regarding hyperuricemia, dyslipoproteinemia, and
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Table 1. Genotype frequencies for the −1082IL-10, −308TNF-a, TGF-b1 (codon 10, 25), −174IL-6 and +874IFN-c single nucleotide
polymorphisms in a cohort of long-term renal transplant patients
Hyperuricemia Type 2/steroid-induced DM Dyslipoproteinemia Hypertension
Genotype Yes No Yes No Yes No Yes No
−1082IL-10 N = 178 N = 80 N = 51 N = 207 N = 193 N = 65 N = 219 N = 39
AA (N = 57) 0.208 0.250 0.176 0.232 0.212 0.246 0.219 0.231
AG (N = 58) 0.281e 0.100 0.235 0.222 0.244 0.169 0.228 0.205
GG (N = 143) 0.511 0.650 0.589 0.546 0.544 0.585 0.553 0.564
−308TNF-a N = 186 N = 87 N = 53 N = 220 N = 208 N = 65 N = 237 N = 36
AA (N = 6) 0.021 0.023 0 0.027 0.019 0.031 0.021 0.028
AG (N = 77) 0.258 0.333 0.302 0.278 0.264 0.338 0.279 0.305
GG (N = 190) 0.721 0.644 0.698 0.695 0.717 0.631 0.700 0.667
+874IFN-c N = 188 N = 87 N = 54 N = 221 N = 209 N = 66 N = 234 N = 41
AA (N = 86) 0.324 0.288 0.463a 0.276 0.311 0.318 0.312 0.317
AT (N = 137) 0.511 0.471 0.370 0.529 0.493 0.515 0.500 0.488
TT (N = 52) 0.165 0.241 0.167 0.194 0.196 0.167 0.188 0.195
−174IL-6 N = 189 N = 86 N = 54 N = 221 N = 209 N = 66 N = 234 N = 41
CC (N = 62) 0.228 0.221 0.241 0.222 0.220 0.243 0.227 0.219
CG (N = 127) 0.492 0.395 0.444 0.466 0.464 0.454 0.470 0.415
GG (N = 86) 0.280 0.384 0.315 0.312 0.316 0.303 0.303 0.366
TGF-b1 10 N = 187 N = 89 N = 54 N = 222 N = 208 N = 68 N = 235 N = 41
CC (N = 50) 0.176 0.191 0.223 0.171 0.178 0.191 0.183 0.171
CT (N = 111) 0.380 0.449 0.407 0.401 0.433 0.309 0.417 0.317
TT (N = 115) 0.444 0.360 0.370 0.428 0.389 0.500 0.400 0.512
TGF-b1 25 N = 174 N = 102 N = 57 N = 219 N = 207 N = 69 N = 245 N = 31
CC (N = 11) 0.040 0.039 0.017 0.046 0.029 0.072 0.041 0.032
CG (N = 37) 0.075 0.235d 0.123 0.137 0.111 0.203 0.131 0.161
GG (N = 228) 0.885b 0.726 0.860 0.817 0.860c 0.725 0.828 0.807
Statistical significance was calculated from the observed absolute numbers using Yate’s corrected chi-square test.
aP = 0.0127; bP = 0.013; cP = 0.0171; dP = 0.0003; eP = 0.0022.
T2/SIDM. No differences in genotype frequencies were
found between the hypertensives and normotensives for
all cytokines studied.
In order to prove that factors such as post-transplant
time period, type of native disease, and type of donor
were not confounding variable for the observed genotype
related associations we performed MANOVA. We did
not find any significant correlations. This suggests that
the genotype related association is an independent risk
factor.
DISCUSSION
In the present study we established for the first time
an association of the +874IFN-c AA genotype with
T2/SIDM, the TGF-b1 (codon 25) GG genotype with
post-transplant hyperuricemia and dyslipoproteinemia,
and the −1082IL-10 AG genotype with post-transplant
hyperuricemia.
We found an association of the polymorphism within
the first intron of the IFN-c gene with T2/SIDM. It is well
known that transplant patients treated with tacrolimus
are at higher risk for the development of post-transplant
diabetes mellitus. Therefore, we analyzed the frequency
of tacroloimus usage across these groups. We did not find
any significant differences. This indicates that the ob-
served association between IFN-gamma gene polymor-
phism and PTDM is independent on tacrolimus usage.
To our knowledge, this is the first description of pos-
itive association of the +874IFN-c AA genotype with
the indicated pathologic condition. Recently, it has been
reported on the association of type 1 diabetes mellitus
with the 12-CA-repeat allele within the first intron of the
IFN-c gene [17]. Importantly, there is a correlation be-
tween this 12-CA-repeat allele and the presence of the
T allele at an SNP located at the +874 position, coin-
ciding with a putative NF-jB binding site that might be
important in the induction of constitutively high IFN-c
production. Therefore, the +874IFN-c TT genotype has
been suggested to be associated with high IFN-c produc-
tion [18].
To provide a reasonable explanation for the observed
association of T2/SIDM with the +874IFN-c AA geno-
type we put forward the following hypothesis (Fig. 1).
The type 1 diabetes promoting and the type 2 dia-
betes promoting effects of the +874TT and +874AA
genotype, respectively, indicate two seemingly oppos-
ing faces (the Yin and the Yang) of the +874IFN-
c gene polymorphisms. “High producer” homozygous
+874TT subjects generate more IFN-c comparatively to
those bearing the +874AA genotype, which has been as-
cribed to low IFN-c production [19]. Hence, the level of
IFN-c expression/secretion might differentially con-
tribute to the pathogenesis of either type 1 or type 2 di-
abetes. While the predominant mechanism of the type 1
diabetes-promoting effect of IFN-c is a b-cell targeted
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High IFN-γ production
Low IFN-γ production
β-cell targeted T-cell mediated
cytotoxicity and direct β-cell
injury
Type 1 diabetes mellitus
Type 2 diabetes mellitus
+874 AA genotype
+874 TT genotype
Lack of IFN-γ mediated
metabolic effects on β cells
and on insulin-sensitive
glucose uptake
Fig. 1. The Yin-Yang hypothesis of the +874IFN-c gene polymorphism. For details, please refer to the text.
T cell-mediated cytotoxicity [20], the nature of an asso-
ciation between low IFN-c production and susceptibility
to type 2 diabetes mellitus remains to be elucidated. Hy-
pothetically, the lack of IFN-c metabolic effects on (1)
pancreatic b-cells, which persistently run IFN-c signaling
as long as the cytokine is present [21]; and (2) on insulin-
sensitive glucose uptake in target tissues [12] could result
in insulin deficiency and/or insulin resistance favoring the
type 2 diabetes mellitus. Noteworthy, cytokine inducers
of bacterial origin (OK-432, BCG) lowered fasting blood
glucose levels, and improved glucose tolerance in type 2
diabetic KK-Ay mice [22]. To further evaluate whether
aberrant IFN-c expression predisposes to abnormal glu-
cose turnover, an experimental approach using IFN-c
knock-out mice might be an option.
To the authors’ knowledge, the TGF-b1 polymorphism
has not yet been studied with respect to post-transplant
nonimmunologic complications. We analyzed two single-
nucleotide polymorphisms in the DNA sequence encod-
ing the leader sequence of the TGF-b1 protein, located
at position +869 (codon 10, T→C, leucine→proline)
and position +915 (codon 25, G→C, arginine→proline).
Here, we report on the association of the TGF-b1
(codon 25) GG (Arg25/Arg25) genotype with both post-
transplant dyslipoproteinemia and hyperuricemia. Note-
worthy, production levels of TGF-b1 have been shown to
be under genetic control of SNPs in both the promoter
region and the first exon of the TGF-b1 gene [23]. The
TGF-b1 (codon 25) G (Arg25) allele has been correlated
with high TGF-b1 production [24]. Therefore, our find-
ings suggest that high TGF-b1 production might be a risk
factor for dyslipoproteinemia in long-term renal trans-
plant patients bearing the TGF-b1 (codon 25) GG geno-
type. In line with this, an increased TGF-b1 expression
is associated with up-regulated body mass index and ab-
dominal adipose tissue in morbid obesity [25], an obser-
vation clearly indicating links between lipid metabolism
and production levels of TGF-b1. Moreover, long-term
exposure to TGF-b1 is capable of suppressing leptin ex-
pression in human adipose tissue [26], the phenomenon,
per se, coupled with insulin resistance, and observed dur-
ing fasting and diabetes and in genetically obese ob/ob
mice [27].
In animal models, over-expression of TGF-b1 causes
multiple tissue lesions [28]. Therefore, it is tempting to
speculate that high producer TGF-b1 25 GG patients
may develop secondary hyperuricemia resulting from
TGF-b1–dependent tissue destruction.
The frequency of the−1082IL-10 AG genotype was sig-
nificantly higher in the hyperuricemic patients compared
with the control patients. To this point, no associations of
IL-10 gene SNPs with uric acid levels have been reported.
However, it is known that IL-10 gene SNPs or SNP hap-
lotypes affect production levels of IL-10 [29]. Specifically,
Turner et al [30] demonstrated a difference in IL-10 secre-
tion in association with the presence or absence of an “A”
allele at position –1082 of the human IL-10 promoter. In
the light of this, one could surmise that genetically deter-
mined individual variations in IL-10 secretion may play a
role in the development of post-transplant hyperuricemia
in long-term renal transplant patients.
CONCLUSION
Our observations support the idea that SNP-
determined variations in IFN-c, TGF-b1, and IL-10
secretion capacity (“high producer” and “low producer”
alleles) may play a role in the development of non-
immunologic post-transplant complications. Hence, the
assessment of respective cytokine gene SNPs may po-
tentially allow more accurate prediction of nonim-
munologic complications and appropriate adjustment of
pre-emptive treatments in long-term transplant patients.
Moreover, it will help to outline novel research areas for
basic studies of T2/SIDM and dyslipoproteinemia.
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To further elucidate the complex network of trans-
interactive cytokine genes influencing the development
of nonimmunologic post-transplant complications, deter-
mination of cytokine regulatory SNP haplotypes will be
required.
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